The use of Ki-67, a proliferation marker, for guiding treatment decisions in breast cancer patients

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Joseph Gligorov, MD, PhD, of Sorbonne Université, Paris, France, discusses some of the difficulties with using Ki-67, a nuclear protein associated with cellular proliferation, as a predictive parameter for response to adjuvant chemotherapy in breast cancer patients.

This content is supported by Genomic Health, Inc.

Year of Production:
Running Time:


Comments are closed.